Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
36.21
+0.33 (0.92%)
At close: Nov 18, 2025, 4:00 PM EST
36.29
+0.08 (0.22%)
After-hours: Nov 18, 2025, 4:08 PM EST
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $15.00M in the twelve months ending September 30, 2025. In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%.
Revenue (ttm)
$15.00M
Revenue Growth
-90.00%
P/S Ratio
100.32
Revenue / Employee
$115,385
Employees
130
Market Cap
1.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 6 days ago - Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 22 days ago - Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal - Seeking Alpha
- 5 weeks ago - Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
- 5 weeks ago - Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - GlobeNewsWire
- 2 months ago - Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - GlobeNewsWire
- 3 months ago - Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire